Vir Biotechnology (VIR) late Monday said European regulators are expected to approve its product candidates to treat a relatively rare form of hepatitis and liver disease as an orphan drug.
A European Medicines Agency advisory panel recommended approving tobevibart and elebsiran as an orphan drug for the treatment of chronic hepatitis delta. The recommendation follows encouraging preliminary data from a phase 2 trial evaluating the efficacy of the drug combination in adults with hepatitis delta infections.
The US Food and Drug Administration in June issued a fast-track designation for the tobevibart and elebsirann, which will expedite the review process.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。